GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent

by Business Wire • 2025/06/26 • 0 Comments

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ®, the Company’s gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropath

← Senators question CDC nominee Monarez, including about vaccines

Alcon Canada reçoit une reconnaissance mondiale comme l’un des meilleurs employeurs →

Post navigation